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put monitoring such as the esophageal Doppler (ED) and arterial pulse
pressure waveform analysis (APPWA) have been shown to improve
surgical outcomes compared with conventional clinical assessment
(CCA). Objective: To evaluate the cost-effectiveness of these techni-
ques in high-risk abdominal surgery from the perspective of the
French public health insurance fund.Methods: An analytical decision
model was constructed to compare the cost-effectiveness of ED,
APPWA, and CCA. Effectiveness data were deﬁned from meta-
analyses of randomized clinical trials. The clinical end points were
avoidance of hospital mortality and avoidance of major complica-
tions. Hospital costs were estimated by the cost of corresponding
diagnosis-related groups. Results: Both goal-directed therapy strat-
egies evaluated were more effective and less costly than CCA.
Perioperative mortality and the rate of major complications were
reduced by the use of ED and APPWA. Cost reduction was mainly due
to the decrease in the rate of major complications. APPWA wasee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.04.005
uillaum@gmail.com.
ndence to: Legrand Guillaume, Service d'Urologie etdominant compared with ED in 71.6% and 27.6% and dominated in
23.8% and 20.8% of the cases when the end point considered was
“major complications avoided” and “death avoided,” respectively.
Regarding cost per death avoided, APPWA was more likely to be
cost-effective than ED in a wide range of willingness to pay. Con-
clusions: Cardiac output monitoring during high-risk abdominal sur-
gery is cost-effective and is associated with a reduced rate of hospital
mortality and major complications, whatever the device used. The two
devices evaluated had negligible costs compared with the observed
reduction in hospital costs. Our comparative studies suggest a larger
effect with APPWA that needs to be conﬁrmed by further studies.
Keywords: abdominal surgery, arterial pulse pressure waveform
analysis, cost-effectiveness, esophageal Doppler, goal-directed ﬂuid
therapy.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Goal-directed ﬂuid therapy based on cardiac output monitoring
during high-risk surgery is associated with better tissue perfu-
sion, decreased risk of perioperative complications, improved
postoperative rehabilitation, and reduction in hospital length of
stay compared with standard hemodynamic monitoring based on
clinical parameters (blood pressure, heart rate, and urinary out-
put) or use of a central venous catheter [1–3].
Initially, the criterion standard for cardiac output monitoring
was the thermodilution method, which required the insertion of
a pulmonary artery catheter, an invasive procedure with signiﬁ-
cant morbidity and whose clinical beneﬁt has been questioned
[4].Over the last 15 years, several new minimally invasive devices
have been developed and have become commercially available:
esophageal Doppler (ED), the most widely used technique, meas-
ures blood ﬂow velocity in the descending thoracic aorta through
a probe inserted in a patient’s esophagus during general anes-
thesia. This technique allows for continuous estimation of the
corrected ﬂow time, stroke volume, and cardiac output. A
predetermined decision algorithm is used to guide ﬂuid therapy
according to the cardiac output variation. Another minimally
invasive technique, the arterial pulse pressure waveform analysis
(APPWA), allows a similar way to measure continuous cardiac
output thanks to an arterial catheter connected to a monitor
analyzing pulse pressure waveform.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Transplantation, Hôpital Saint-Louis. 1 Avenue Claude Vellefaux.
APPWA + CCA 
Fig. 1 – Economic decision model tree comparing three
strategies of intraoperative hemodynamic monitoring.
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have shown clinical beneﬁt with ED and APPWA compared with
conventional clinical assessment (CCA) in high-risk surgery and
high dependency units (HDUs) [1,2,5,6]. Two systematic reviews
have recently studied the contribution of ED in terms of reduction
in the rate of complications, hospital length of stay, and mortality
compared with CCA [5,7]. In the United Kingdom, the National
Institute of Health and Care Excellence published in 2011 good
practice guidelines for ED and has argued that in an enhanced
recovery program, the cost saving per patient when ED was used
instead of a central venous catheter in the perioperative period
was about £1100 based on a 7.5-day hospital stay [8]. These
recommendations, however, have been discussed because they
were based on a small number of RCTs with quite small and
heterogeneous populations: Interventions studied were as
diverse as cardiac, orthopedic, and abdominal surgery, in oper-
ative rooms or in HDUs [9]. More recently, other RCTs have been
published focusing on abdominal surgery [10–15], but their
results remain to be synthetized.
Actually, cardiac output monitoring during high-risk surgery is
not systematically implemented and costs could be a barrier to its
adoption. This is especially disturbing because it can be suspected
that, depending on the device used, morbidity, mortality, and
length of stay could be different. Economic evaluation can help
decision makers reach an optimal allocation of resources [16].
To date, only two economic studies have evaluated ED and
have shown that it is an efﬁcient strategy compared with CCA
alone [5,17], but, to our knowledge, costs and consequences of
using other techniques of minimally invasive cardiac output
monitoring such as APPWA have never been investigated.
The aim of this study was to evaluate the cost-effectiveness
ratio of ED and APPWA in comparison to that of CCA in
intermediate- and high-risk abdominal surgery from the French
public health insurance fund perspective.APPWA, arterial pulse pressure waveform analysis; CCA,
conventional clinical assessment; ED, esophageal Doppler.Methods
Economic Model
A decision tree was constructed to compare the cost-effectiveness
ratios of three hemodynamic monitoring and ﬂuid therapy strat-
egies in intermediate- and high-risk abdominal surgery (Fig. 1).
Interventions compared were CCA, including measurements of
heart rate, blood pressure, and urinary output with or without
central venous catheter monitoring; measurement of cardiac out-
put with ED (CardioQ-ODM, Deltex Medical) associated with stand-
ard monitoring (ED þ CCA); and measurement of cardiac output
with APPWA (Vigileo/FloTrac, Edwards Lifesciences) associated
with standard monitoring (APPWA þ CCA).
Following each strategy, three individual outcomes were possi-
ble: death of the patient, occurrence of major complications, and
discharge without any major complication, occurring with a prob-
ability P depending on the clinical effectiveness of each outcome.
The time horizon considered was the hospital period, extend-
ing from entrance until hospital discharge. It was assumed that
hemodynamic optimization and ﬂuid administration during sur-
gery would not inﬂuence outcomes after discharge. This assump-
tion was also made in all the RCTs.
Clinical-Effectiveness Data
The two effectiveness criteria considered were avoidance of
mortality and avoidance of major complications. A complication
was considered as major when resulting in hospitalization in the
intensive care unit or revision surgery, reported as grade 3 or 4
complications in Dindo et al.’s classiﬁcation [18].A comprehensive review of the literature was performed in
January 2013 without any time or language restriction using
PUBMED, EMBASE, and COCHRANE databases, and complementary
research was performed on the basis of the bibliography section of
articles, unpublished studies, and proceedings from scientiﬁc confer-
ences. Key words used were “esophageal Doppler,” “goal directed
therapy,” hemodynamic,” “arterial pulse pressure waveform analy-
sis,” and “surgery.” All RCTs comparing CCA with a minimally
invasive method of cardiac output monitoring during abdominal
surgery and related mortality or major complications were included,
whatever the number of patients. Studies conducted in pediatrics, in
HDUs or in nonabdominal surgery, were excluded. A second author
performed data extraction independently, and the methodological
quality of the trials was assessed using the Jadad score [19].
Based on the selected articles, meta-analyses of effectiveness
data were performed to estimate probabilities.
CCA
For CCA, the probability of an event (death or major complication)
corresponded to the overall proportion of the event, and the 95%
conﬁdence interval (CI) was calculated from a meta-analysis of
single-proportion control groups that we performed, considering
all RCTs and comparing the CCA strategy with another strategy
(ED þ CCA and APPWA þ CCA). These values were used for the
base-case analysis.
ED and APPWA
For both alternatives to CCA (ED þ CCA and APPWA þ CCA), the
probability for an event (death or major complication) was
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 0 5 – 6 1 3 607estimated as the product of the probability for the CCA strategy
and the relative risk (RR) associated with the corresponding
alternative. RR was used instead of pooled proportion to estimate
probabilities of event because no event was observed in the
intervention groups of some trials.
Meta-analyses of RCTs were conducted to assess the RR (with
95% CI) of mortality and major complications for ED and APPWA
compared with CCA. The Mantel-Haenzel method with ﬁxed-
effect model was used. We drew funnel plots to check for the
existence of publication bias.
Cost Data
Only direct medical costs were considered, i.e., hospital costs and
costs of equipment. Hospital costs were valued as the cost of the
corresponding diagnosis-related group (DRG). In France, each
hospital stay is assigned to a DRG on the basis of principal
diagnosis, procedures performed, length of stay, and level of
severity (comorbidities and complications). These costs include
expenses of clinical activity, costs of supporting activities, logistic
costs, and management overheads and expenses. There is one
national DRG system in France used as the basis of hospital
payment since 2004–2005. As recommended by the Department
of Economics and Public Health Assessment of the French
National Authority for Health (Haute Autorité de Santé) in 2012,
the preferred source of data to approximate the production cost
of a hospital stay is the national cost study (Etudes Nationales de
Coûts à méthodologie Commune [ENCC]), performed by the
Technical Agency for Hospital Information (Agence Technique
de l’Information sur l’Hospitalisation). The data from the ENCC
are based on the hospital-cost accounting system by DRGs. The
production costs from the ENCC represent average costs, with the
limit of masking some variations between establishments [20].
We took this into account in the sensitivity analysis.
The costs used at baseline and for sensitivity analysis were
the DRG costs for colic and rectal surgeries performed in a public
hospital, ranging from levels 1 to 4 based on comorbidities and
complications. Levels 1 or 2 corresponded to colic or rectal
surgery with minor comorbidities (i.e., controlled hypertension
or diabetes) or complication(s) (i.e., wall abscess or minor infec-
tion). Levels 3 or 4 corresponded to colic or rectal surgery with
major complication(s) (i.e., peritonitis, myocardial infarction,
acute heart failure, stroke, sepsis). Because death occurs most
generally after a major complication, level 3 valued death at
baseline.
Equipment costs applied only to devices monitoring cardiac
output. It was assumed that CCA costs were included into hospital
costs. For ED and APPWA, equipment costs were provided by
manufacturers and included costs of disposable probes and
monitoring equipment. The prices provided by the manufacturers
were list prices that could be negotiated by each hospital depend-
ing primarily on the number of surgical procedures provided per
year. This was taken into account in the sensitivity analysis.
Equipment cost for each usage of the system was calculated.
The calculation assumed that the equipment would last 5 years
and would be used 300 times per year (other utilization rates were
tested in sensitivity analyses). Capital costs of devices were
converted to an equivalent annual cost by applying a 5% discount
rate to adjust for consecutive years of usage.
The costs used in the present analysis are presented in
2011 euros.
Cost-Effectiveness Analysis
The cost-effectiveness ratio of each strategy was calculated and
compared in pairs. Incremental cost-effectiveness ratios (ICERs)
were calculated: cost per major complication avoided and costper death avoided. A more effective and less costly strategy was
considered a dominant strategy. Conversely, a less effective and
more expensive strategy was considered a dominated strategy.
ICERs were not calculated in these cases.
Sensitivity Analysis
One-way deterministic sensitivity analyses were performed by
individually varying each variable of cost and effectiveness to
identify those with the greatest inﬂuence on the results. Upper
and lower bounds of 95% CI were used to deﬁne minimal and
maximal values of probabilities.
Probabilistic sensitivity analysis was performed using the
Monte-Carlo method to consider the impact of the uncertainty
associated with different values of the variables on the cost-
effectiveness ratio. Several values were randomly assigned to
different costs and effectiveness variables of the model on the
basis of a probability distribution. We considered that the
probabilities were distributed according to a beta distribution,
and RRs were distributed according to a lognormal distribution.
For costs, we chose a triangular distribution with lower and upper
bounds used in the one-way sensitivity analysis. An overall
estimate of the distribution of the cost-effectiveness ratio was
obtained by performing 1000 iterations, illustrated by cost-
effectiveness planes. The results of this analysis are also pre-
sented as cost-effectiveness acceptability curves. Central to the
assessment of cost-effectiveness is the value that society would
place on gaining an additional unit of effectiveness. Therefore, by
knowing a particular willingness-to-pay (WTP) value on the
horizontal axis, the probability that an option will be cost-
effective can be obtained from the vertical axis.Results
Clinical Effectiveness
A comprehensive literature search identiﬁed a total of 13 RCTs: 10
RCTs comparing CCA with ED þ CCA [10–13,15,21–25], including
three unpublished studies [13,15,22] and three RCTs comparing
CCA with APPWA þ CCA in high-risk abdominal surgery [6,26,27].
None has been deemed to be of inadequate methodological
quality (Table 1).
The probability of mortality and major complications with
CCA calculated from pooled data from 13 (N ¼ 653) [6,10–13,15,21–
27] and 7 (N ¼ 366) studies [6,10–12,21,22,24] was 0.04 (95% CI
0.02–0.07) and 0.16 (95% CI 0.10– 0.24), respectively.
ED was associated with a signiﬁcant decrease in perioperative
mortality when compared with CCA with a ﬁxed-effect model
based on data from 10 studies (N ¼ 1 078) [10–13,15,21–25] (RR ¼
0.47; 95% CI 0.24–0.91). The RR of major complications, calculated
from six studies (N ¼ 603) [10–12,21,22,24], showed a trend toward
better results with ED (RR ¼ 0.69; 95% CI 0.44–1.09) (Fig. 2).
Mortality was two times lower with APPWA than with CCA
based on the meta-analysis of three studies (N ¼ 213) [6,26,27]
(RR ¼ 0.54; 95% CI 0.19–1.51) (Fig. 2). The RR of major complica-
tions with APPWA was calculated from only one study (N ¼ 120)
[6]; it was approximately three times lower than with CCA (RR ¼
0.3; 95% CI 0.13–0.69).
Probability values and their distribution, which were used to
implement the model, are summarized in Table 2. As shown by
the funnel plots of study size against treatment effect, there was
no evidence of publication bias (Fig. 3).
Cost Data
At baseline, a hospital stay without death or major complication
was valued at €9465, corresponding to a DRG of level 2 colic
Table 1 – Characteristics of the selected studies.
Study Intervention N Type of surgery Mean age
(y)
ASA 42 (%) Mean P-
POSSUM
Mean BMI
(kg/m2)
S C S C S C
Srinivasa et al. [10] ED 85 Colorectal 69 72 39 9 9 26.9 26.4
Challand et al. [11] ED 179 Colorectal 66 65.9 30 - -
Brandstrup et al.
[12]
ED 150 Colorectal 66.9 68.1 16 - 24.8 25.6
Karas et al. [13] ED 91 Colorectal 57 57 80 8 8 27.5 27.7
Szturz et al. [15] ED 230 Nephrectomy,
prostatectomy,
cystectomy
61.5 62.8 - - -
Conway et al. [21] ED 57 Colorectal 66.5 67.5 - - -
Dodd et al. [22] ED 40 Colorectal 76.3 76.3 - - 25.3 23.9
Wakeling et al. [23] ED 134 Colorectal 69.1 69.6 - 17 18 24.5 26
Noblett et al. [24] ED 108 Colorectal 62.3 67.6 - 16 16 25.9 26.4
Senagore et al. [25] ED 64 Colorectal - - - -
Benes et al. [6] APPWA 120 Colorectal,
pancreatic,
vascular
66.7 66.3 79 21 20 -
Lopes et al. [26] APPWA 33 Colorectal, gastric,
liver, urologic
63 62 82 - 24 23
Mayer et al. [27] APPWA 60 Colorectal, gastric,
esophagus, liver
73 72 - 22 21 26.4 25.8
APPWA, arterial pulse pressure wave analysis; ASA, American Society of Anesthesiology; BMI, body mass index; C, control group; ED,
esophageal Doppler; P-POSSUM, physiologic component of Physiologic and Operative Severity Score for the enUmeration of Mortality and
Morbidity; S, study group.
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(lower bound of level 1 colic surgery) to €12,118 (upper bound of
level 2 rectal surgery). The cost of a hospital stay when at least
one major complication occurred was valued at €13,900, corre-
sponding to a DRG of level 3 colic surgery, with values used for
sensitivity analyses ranging from €12,213 (lower bound of level 3
colic surgery) to €31,667 (upper bound of level 4 rectal surgery).
Baseline value for a death was €13,900, corresponding to level 3 of
colic surgery, and values used for sensitivity analyses ranged
from €6,452 (lower bound of level 1 colic surgery) to €31,667
(upper bound of level 4 rectal surgery) [31].
Manufacturers provided the costs of devices. For ED, the cost
of the monitor (CardioQ-ODM) was €13,300, the equivalent annual
cost was €3,072, and the cost of one probe was €150. For APPWA,
the cost of the monitor (Vigileo/FloTrac) was €10,166, the equiv-
alent annual cost was €2,348, and the cost of one probe was €167.
Based on a mean of 300 procedures per year with bounds used for
sensitivity analyses from 100 to 500, the total cost per patient was
€160 (€156–€180) and €174 (€171–€191), respectively, for ED
and APPWA.
Cost-Effectiveness Analysis
Avoided Major Complications
At baseline, the two goal-directed ﬂuid therapy strategies were
more effective and less costly compared with CCA. Moreover,
APPWA was dominant compared with ED, as shown in Table 3.
In one-way sensibility analysis, APPWA was always dominant
compared with CCA, and ED was dominant most of the time
compared with CCA. ED was dominant over APPWA in three
situations, but was dominated in all others. The results were
sensitive to variation in probabilities of death and major compli-
cations but not to variation in cost data (Table 3).
In probabilistic sensitivity analysis, APPWA and ED were
dominant compared with CCA in 97.3% and 76.1% of cases,respectively, and were dominated in 0% and 13.3% of cases,
respectively. ED compared with APPWA was dominant in only
23.8% of cases and was dominated in 71.6% of cases (Fig. 4). In the
remaining 4.6% of cases, the probability of being cost-effective
depended on the WTP for a major complication avoided.
Avoided Death
At baseline, the two goal-directed ﬂuid therapy strategies were
more effective and less costly compared with CCA. ED was more
effective but more costly than APPWA, with an ICER equal to
€79,600 per avoided death (Table 3).
In one-way sensitivity analysis, ED and APPWA were largely
dominant compared with CCA. When the minimum value was
applied to the probability of death in the CCA strategy, the latter
became more effective and more costly compared with the two
goal-directed strategies. ED was dominant over APPWA in three
situations and was dominated in two situations. In other cases,
the ICER between the two strategies ranged from €11,177 to
€457,140 per avoided death (Table 3).
In probabilistic sensitivity analysis, APPWA and ED were
dominant compared with CCA in 92.9% and 69.5% of cases,
respectively, and were dominated in 0.2% and 4.1%, respectively.
ED compared with APPWA was dominant in 20.8% and was
dominated in 27.6% of cases (Fig. 4). Figure 5 shows that APPWA
is more likely than ED to be cost-effective over a wide range of
WTP. The difference in probabilities is larger (0.4) when the WTP
is close to zero than when the WTP is at €100,000 (0.2).Discussion
This economic study is the ﬁrst to compare several methods of
intraoperative minimally invasive cardiac output monitoring
with standard monitoring based on the measurement of clinical
parameters.
Study
Fixed effect model
Heterogeneity: I-squared=0%, tau-squared=0, p=0.7652
SRINIVASA
CONWAY
WAKELING
BRANDSTRUP
NOBLETT
CHALLAND
SENAGORE
DODD
BERGAMASCHI
SZTURZ
Events
 0
 0
 0
 1
 0
 5
 0
 1
 0
 3
Total
529
 37
 29
 64
 71
 51
 89
 21
 20
 32
115
Experimental
Events
 2
 1
 1
 1
 1
 4
 0
 2
 0
12
Total
549
 37
 28
 64
 79
 52
 90
 22
 20
 42
115
Control
0.01 0.1 1 10 100
Risk Ratio
RR
0.47
0.20
0.32
0.33
1.11
0.34
1.26
0.50
0.25
95%-CI
 [0.24;  0.91]
 [0.01;  4.03]
 [0.01;  7.58]
 [0.01;  8.03]
 [0.07; 17.46]
 [0.01;  8.15]
 [0.35;  4.55]
 [0.05;  5.08]
 [0.07;  0.86]
W(fixed)
100%
 9.6%
 5.9%
 5.8%
 3.7%
 5.7%
15.3%
 0.0%
 7.7%
 0.0%
46.3%
Study
Fixed effect model
Heterogeneity: I-squared=27.9%, tau-squared=0.1512, p=0.2255
SRINIVASA
CONWAY
BRANDSTRUP
NOBLETT
CHALLAND
DODD
Events
 7
 0
 9
 1
 5
 4
Total
297
 37
 29
 71
 51
 89
 20
Experimental
Events
 7
 4
 7
 7
 9
 5
Total
306
 37
 28
 79
 52
 90
 20
Control
0.01 0.1 1 10 100
Risk Ratio
RR
0.69
1.00
0.11
1.43
0.15
0.56
0.80
95%-CI
 [0.44; 1.09]
 [0.39; 2.57]
 [0.01; 1.90]
 [0.56; 3.64]
 [0.02; 1.14]
 [0.20; 1.61]
 [0.25; 2.55]
W(fixed)
100%
17.9%
11.7%
17.0%
17.7%
22.9%
12.8%
Study
Fixed effect model
Heterogeneity: I-squared=0%, tau-squared=0, p=0.7277
BENES
MAYER
LOPES
Events
 1
 2
 2
Total
107
 60
 30
 17
Experimental
Events
 2
 2
 5
Total
106
 60
 30
 16
Control
0.1 0.5 1 2 10
Risk Ratio
RR
0.54
0.50
1.00
0.38
95%-CI
 [0.19; 1.51]
 [0.05; 5.37]
 [0.15; 6.64]
 [0.08; 1.67]
W(fixed)
100%
21.9%
21.9%
56.3%
Fig. 2 – Meta-analysis of perioperative mortality and major complication risk with ED and APPWA compared with
conventional clinical assessment. APPWA, arterial pulse pressure waveform analysis; CI, conﬁdence interval; ED, esophageal
Doppler; RR, relative risk.
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optimizing cardiac output (regardless of the device used) provides
better results. In most cases, this strategy was more effective in
terms of both reduction in perioperative mortality and major
complications and was less costly. Better results were achieved with
APPWA compared with ED, but varied with the end point consid-
ered. The interpretation of these results must take into account the
uncertainty associated with the values assigned to the various
parameters of cost and effectiveness in the model. According to
one-way sensitivity analysis, the most critical parameter was the
transition probabilities in different health states (i.e., the probability
of death and the probability of having major complication).
Effectiveness data were calculated from meta-analyses of
several rigorously selected RCTs according to the Mantel-
Haenszel method with a ﬁxed-effect model, which provides
robustness to this study. These meta-analyses took into consid-
eration recent studies [10–13,15] that were not evaluated inprevious meta-analyses [1,2,5,7,28]. Some unpublished studies
have also been collected to obtain comprehensive data [13,15,22].
Regarding ED, several meta-analyses have demonstrated a clin-
ical beneﬁt in abdominal surgery [2,17,28]. A recent one con-
ducted by Srinivasa et al. [29] showed that ED did not inﬂuence
length of hospital stay or complications after colorectal surgery.
The authors note that, unlike earlier studies, newer trials did not
show any beneﬁt from cardiac monitoring and suggest a possible
publication bias [29]. All the studies selected by Srinivasa et al. in
their meta-analysis have been included in ours. These studies
concerned only colorectal surgery. In our study, four additional
RCTs, including digestive and urologic surgery, were used. This
could explain why our results are different. To our knowledge,
our study is the ﬁrst to demonstrate a statistically signiﬁcant
reduction in mortality compared with CCA.
Concerning APPWA, the literature was poor, few RCTs have
been published, and neither meta-analysis nor economic studies
Table 2 – Clinical-effectiveness data used in base-case and sensitivity analysis.
Intervention Outcome Studies Value SD 95% CI Distribution
RR ED þ CCA vs. CCA Mortality (I) [10–13,15,21–25] 0.47 0.34 0.24 0.91 Lognormal
Major complication
(II)
[10–12,21,22,24] 0.69 0.23 0.44 1.09
APPWA þ CCA vs.
CCA
Mortality (III) [6,26,27] 0.54 0.52 0.19 1.51
Major complication
(IV)
[6] 0.32 0.13 0.69
Probability CCA Mortality (V) [6,10–13,15,21–27] 0.039 0.061 0.016 0.068 Beta
Major complication
(VI)
[6,10–12,21,22,24] 0.163 0.093 0.099 0.239
ED þ CCA Mortality (I)  (V) 0.018 0.004 0.062
Major complication (II)  (VI) 0.112 0.044 0.261
APPWA þ CCA Mortality (III)  (V) 0.021 0.003 0.103
Major complication (IV)  (VI) 0.052 0.013 0.165
Note. Probability to have an event in the control intervention group (ED þ CCA or APPWA þ CCA) is estimated as the product of the probability
for the control group (CCA) and the RR associated with the corresponding alternative.
APPWA, arterial pulse pressure waveform analysis; CCA, conventional clinical assessment; CI, conﬁdence interval; ED, esophageal Doppler; RR,
relative risk.
Values in bold were used as probability p in the model.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 0 5 – 6 1 3610were available. We were the ﬁrst to conduct a meta-analysis of
three studies on mortality risk [6,26,27]. Only one study was
available for the risk of major complications, and this could be a
limitation [6]. Results of such a meta-analysis must be inter-
preted with caution, as suggested by Morris [30] in a recent
editorial. According to Morris, some data have emerged from
evidence-based medicine raising concerns about the safety of
intravascular volume expanders that are being used with goal-
directed ﬂuid therapy.
To date, only one economic study has evaluated ED during
abdominal surgery. In this cost-effectiveness study, conducted by
Maeso et al. [17], strategies were evaluated comparing ED and
CCA with CCA alone. The authors showed that the use of ED was
associated with a statistically signiﬁcant lower rate of total and
major complications, but not of mortality. Cost savings were
mainly due to fewer complications, shorter hospital stays, and
shorter intervention times. Our study used the same design, but
also evaluated another strategy of cardiac output monitoring,
namely, APPWA. The costs related to devices were negligible
compared with hospital costs, whatever the number of annual
procedures. Investment costs should not be an obstacle to device0.02 0.05 0.10 0.20 0.50 1.00 2.00 5.00
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Fig. 3 – Funnel plot of study size against treatment effect. (A) Stu
(B) Studies comparing ED þ CCA vs. CCA for reduction in major
for reduction in mortality. APPWA, arterial pulse pressure wave
esophageal Doppler.acquisition for institutions, given the clinical and economic
beneﬁts of cardiac output monitoring. Choosing between ED
and APPWA, however, remains an issue: One may be tempted
to prefer APPWA, but one should remain cautious because results
are based on the few available studies and depend on the
cost-effectiveness ratios thresholds considered acceptable,
especially when the measure of effectiveness is avoided death.
The choice of a threshold is questionable, and it may be advisable
to refer to the acceptability curve to determine the probability for
one strategy to be more efﬁcient than another, depending of the
decision maker’s WTP [16]. The time horizon chosen in our study
can be discussed. It was assumed that cardiac output
control systems and ﬂuid administration during surgery would
not inﬂuence outcomes after discharge. This assumption
was also made in all the RCTs. If, however, we think about stroke
or myocardial infarction, these major complications probably
have an impact on patient’s morbidity, survival, and/or
quality of life, and also on costs after discharge, and this could
be examined using modeling. The main reason why we
chose this time horizon was for the purpose of local decision
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Table 3 – Results of cost-effectiveness analysis in base-case scenario and in one-way sensitive analysis.
Variable Major complication avoided Death avoided
ED þ CCA vs.
CCA
APPWA þ CCA vs.
CCA
ED þ CCA vs. APPWA
þ CCA
ED þ CCA vs.
CCA
APPWA þ CCA
vs. CCA
ED þ CCA vs. APPWA
þ CCA
Incremental cost (€) 159.3 398.1 238.8 159.3 398.1 238.8
Incremental effectiveness 0.072 0.129 0.057 0.021 0.018 0.003
ICER Dominant Dominant Dominated Dominant Dominant 79,600
Variable Value ICER
Cost per major complication avoided Cost per mortality avoided
ED þ CCA vs.
CCA
APPWA þCCA vs.
CCA
ED þ CCA vs. APPWA þ
CCA
ED þ CCA vs.
CCA
APPWA þ CCA vs.
CCA
ED þ CCA vs. APPWA þ CCA
pD (ED þ CCA) Min 0.004 Dominant Dominant Dominated Dominant Dominant 11,177.1
Max 0.062 1279.3 Dominant Dominated Dominant Dominant Dominated
pC (ED þ CCA) Min 0.044 Dominant Dominant Dominant Dominant Dominant Dominant
Max 0.261 Dominated Dominant Dominated 167,165 Dominant 304,305.0
pD (APPWA þ
CCA)
Min 0.003 Dominant Dominant Dominated Dominant Dominant Dominated
Max 0.103 Dominant Dominant Dominant Dominant 746.1 Dominant
pC (APPWA þ
CCA)
Min 0.013 Dominant Dominant Dominated Dominant Dominant 137,253.3
Max 0.165 Dominant Dominant Dominant Dominant 5,724.4 Dominant
pD (CCA) Min 0.016 Dominant Dominant Dominated 28,657.5 61,883.0 84,033.3
Max 0.068 Dominant Dominant Dominated Dominant Dominant 84,033.3
pC (CCA) Min 0.099 15,565 Dominant Dominated 5,929.5 Dominant 84,033.3
Max 0.239 Dominant Dominant Dominated Dominant Dominant 84,033.3
cC Min 12,213 Dominant Dominant Dominated Dominant Dominant 48,606.3
Max 31,667 Dominant Dominant Dominated Dominant Dominant 457,140.3
cD Min 6,452 Dominant Dominant Dominated Dominant Dominant 91,481.3
Max 31,667 Dominant Dominant Dominated Dominant Dominant 66,266.3
cW Min 6,452 Dominant Dominant Dominated Dominant Dominant 144,293.3
Max 12,118 443.9 Dominant Dominated 1,509.3 Dominant 30,973.3
cED Min 156 Dominant Dominant Dominated Dominant Dominant 82,700.0
Max 180 Dominant Dominant Dominated Dominant Dominant 90,700.0
cAPPWA Min 171 Dominant Dominant Dominated Dominant Dominant 85,033.3
Max 190 Dominant Dominant Dominated Dominant Dominant 78,700.0
APPWA, arterial pulse pressure waveform analysis; cAPPWA, cost of arterial pulse pressure waveform analysis; CCA, conventional clinical assessment; ICER, incremental cost-effectiveness
ratio; pC, probability to have major complication; pD, probability of death; cC, hospital cost when a major complication occurs (in euros); cD, hospital cost when death occurs (in euros); cED,
cost of cardioQ-ODM device (in euros); cAPPWA, cost of Vigiléo/FloTrac device (in euros); cW, hospital cost when no death or complication occurs (in euros); ED, esophageal Doppler.
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Fig. 4 – Incremental cost-effectiveness ratio comparing ED þ CCA vs. CCA, APPWA þ CCA vs. CCA, and ED þ CCA vs. APPWA þ
CCA in probabilistic sensitivity analysis. APPWA, arterial pulse pressure waveform analysis; CCA, conventional clinical
assessment; ED, esophageal Doppler.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 0 5 – 6 1 3612A number of potential biases need to be recognized to
relativize the superiority of cardiac output monitoring compared
with clinical assessment in this study. First, RCTs on cardiac
monitoring are unlikely to be blinded and clinicians might be
more aware of the information provided by these new devices,
which may overestimate their effect. Second, among the various
studies, three were not published and the data were collectedafter contacting the authors. Concerning heterogeneity between
studies, the study by Szturz et al. [15] accounted for 46.3% of
the RR of mortality with ED versus CCA and this possibly
inﬂuences the results, especially because this study also included
oncological urologic surgery (prostatectomy, cystectomy,
nephrectomy), for which outcomes may differ from colorectal
surgery [15]. There was also some heterogeneity between studies
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Fig. 5 – Acceptability curves showing the likelihood of ED to
be cost-effective compared with APPWA at different levels of
willingness to pay for a death avoided (in euros). APPWA,
arterial pulse pressure waveform analysis; ED, esophageal
Doppler.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 0 5 – 6 1 3 613evaluating ED and those evaluating APPWA when the type of
surgery was analyzed: Studies evaluating APPWA included not
only colorectal surgery but also urologic, vascular, and upper
abdominal (liver and pancreatic resection) surgery, whereas ED
studies included only colorectal and urologic surgery. The former,
however, are known to cause more complications, and cardiac
output monitoring would be more beneﬁcial in these situations
because of longer time of surgery, more fragile vascular patients,
and frequent hemodynamic changes related to arterial clamping,
strengthening the argument in favor of APPWA.Conclusions
Cardiac output monitoring during high-risk abdominal surgery is
cost-effective and is associated with a reduced rate of hospital
mortality and major complications, whatever the device used.
The two devices evaluated had negligible costs compared with
the reduction in-hospital costs. Our comparative studies suggest
a larger effect with APPWA that needs to be conﬁrmed by further
studies.
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